Skip to content
value.today

Raptor Pharmaceutical Corp

Total raised
$15 M
1 round on record
Latest round
$15 M
Aug 2010
First round on record
Aug 2010
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Raptor Pharmaceutical Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2010$15 MNo. 1$10 to $50 million

Raptor Pharmaceutical Corp: Raise no. 1, Aug 2010

Investors in this round

24 investors had bought by the notice of Aug 18, 2010: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
$26,752
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$978,910
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher M. Starr · Executive Officer, Director
  • Kim R. Tsuchimoto · Executive Officer
  • Patrice P. Rioux · Executive Officer
  • Thomas E. Daley · Executive Officer
  • Todd C. Zankel · Executive Officer
  • Erich W. Sager · Director
  • Llew L. Keltner · Director
  • Raymond W. Anderson · Director
  • Richard L. Franklin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • JMP Securities LLC (CRD 22208) · San Francisco, CaliforniaSold in CA, CT, FL, IL, NY, TX

Remarks in the notice

  • On fees: “A warrant to purchase 97,952 shares of common stock par value $0.001 at an exercise price of $3.075.”

Signed by Kim R. Tsuchimoto, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 18, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Raptor Pharmaceutical Corp chose not to state its revenue in its newest notice of a funding round (Aug 2010).

    SEC Form D · Aug 2010

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2010

That is all the official record says: Raptor Pharmaceutical Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Raptor Pharmaceutical Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 24 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Raptor Pharmaceutical Corp
NameRoleNamed in
Christopher M. StarrExecutive officerAug 2010
Kim R. TsuchimotoExecutive officerAug 2010
Patrice P. RiouxExecutive officerAug 2010
Thomas E. DaleyExecutive officerAug 2010
Todd C. ZankelExecutive officerAug 2010
Christopher M. StarrDirectorAug 2010
Erich W. SagerDirectorAug 2010
Llew L. KeltnerDirectorAug 2010
Raymond W. AndersonDirectorAug 2010
Richard L. FranklinDirectorAug 2010